Trial Profile
A Phase 3, Single-dose, Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron 0.25 mg Administered as a 30-minute IV Infusion Compared to Palonosetron 0.25 mg Administered as a 30-second IV Bolus for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2021
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary) ; Cisplatin; Dexamethasone; Palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Helsinn; Helsinn Healthcare SA
- 23 Mar 2016 Status changed from recruiting to completed.
- 26 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 25 Sep 2015 New trial record